News

Celularity Inc. Faces Nasdaq Compliance Challenges and Plan

Celularity Inc. Faces Nasdaq Compliance Challenges and Plan

Celularity Inc. Faces Nasdaq Compliance Challenges

Celularity Inc. (Nasdaq: CELU), a pioneering regenerative medicine company specializing in placental-derived cell therapies and advanced biomaterial solutions, recently received a notice from Nasdaq regarding compliance with listing requirements. This notification highlights a recent setback affecting the company’s filing schedule and operational adjustments.

Notification from Nasdaq

On November 21, the Nasdaq Stock Market informed Celularity that the company had failed to submit its Quarterly Report on Form 10-Q for the period ending September 30. This notice indicates that Celularity must provide a plan to rectify its filing delay and regain compliance by January 20, 2025. Until this plan is accepted by Nasdaq, Celularity's shares will continue to trade under their existing symbols; CELU for common stock and CELUW for warrants.

Compliance Plan Submission

To address this compliance issue, Celularity is actively preparing a corrective plan which must be submitted by the specified deadline. If Nasdaq accepts this plan, the company will have until May 13, 2025, to implement it successfully. Despite the stringent timeline, Celularity is focused on identifying available options that will facilitate the pathway to compliance.

Challenges in Financial Reporting

Celularity is navigating significant challenges associated with its financial reporting processes. The recent filing delays stem from a backlog as the company works diligently to catch up on previous submissions, including first and second-quarter reports for 2024, which were filed successfully ahead of the Q3 Form 10-Q. This indicates that the company is on a path to improving its overall reporting infrastructure.

Company Commitment to Improvements

Robert J. Hariri, M.D., Ph.D., the founder and CEO, has underscored the company’s commitment to enhancing its financial reporting capabilities. He expressed optimism about the completion of the upcoming Q3 filing and reassured stakeholders of the company's dedication to timely and transparent reporting. Hariri emphasized that these improvements are essential for Celularity's long-term success and compliance with Nasdaq requirements.

About Celularity Inc.

Celularity Inc. stands out in the regenerative medicine sector, focusing on developing innovative biomaterials and allogeneic cell therapies sourced from the postpartum placenta. Their therapeutic programs aim to address a variety of age-related conditions, including degenerative diseases and cancer, making effective use of advanced techniques like CAR T-cell therapy and natural killer (NK) cell application.

Significance of Placental Solutions

The company believes strongly in the potential of placental-derived therapies. This unique biological resource not only offers abundant availability but also presents significant opportunities to meet unmet medical needs globally. Celularity strives to provide accessible, efficacious, and affordable therapies to improve patient outcomes.

Investor and Media Contacts

For inquiries about investments, stakeholders can reach out to Carlos Ramirez, Senior Vice President at Celularity Inc. For media-related matters, Raquel Cona and Michaela Fawcett from KCSA Strategic Communications are available to provide information and updates.

Frequently Asked Questions

What triggered the Nasdaq notification for Celularity Inc.?

Celularity Inc. received a notification from Nasdaq due to its failure to file the Quarterly Report on Form 10-Q in time.

What steps is Celularity taking to regain compliance?

The company plans to submit a detailed plan to Nasdaq by January 20, 2025, outlining steps to achieve compliance.

Who is leading Celularity Inc.?

Celularity is led by Robert J. Hariri, M.D., Ph.D., who is the founder and CEO, focusing on improving financial reporting practices.

What types of therapies does Celularity offer?

Celularity develops placental-derived allogeneic cell therapies and advanced biomaterials, addressing various health issues including aging-related diseases and cancer.

How can investors find more information about Celularity?

Investors can visit the company’s website or contact investor relations for the latest updates and detailed information on their operations.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Truss Financial Tackles Home Equity Closing Delays

Updated Category News Views 24

Truss Financial Group's Bold Move Against Closing Delays In real estate, time is money. Even the most casual market observer could tell you delays can slice through a deal like a hot knife through butter. That's the headache home equity borrowers face, blindsided by closing delays that sneak up on them without warning. An Industry Bottleneck Finally Addressed Enter Truss...

Continue Reading
Northern Jet Names Veteran Matthew Harris as CEO

Updated Category News Views 34

Fresh Leadership at Northern Jet Well, if you didn’t see this coming, you’ve been snoozing on the tarmac. Northern Jet, no stranger to the skies after three decades, just roped in Matthew Harris as their new CEO from October 2, 2026. They're pulling in this hotshot with more than 25 years riding the turbulence of private aviation. And listen to this: his marching...

Continue Reading
JiMMYBAR! Expands Creatine Market with Target Launch

Updated Category News Views 29

JiMMYBAR! Breaks New Ground in Supplements You ever notice how some companies just know how to shake things up? Take JiMMYBAR!, for instance. The moment I read they’re making moves to get their Creatine + Protein bars into Target stores nationwide, starting October 4, I thought, “That’s one way to drag creatine out from the dusty tub and onto the shelves of...

Continue Reading
Community Banks Missing $106B Lending Opportunity?

Updated Category News Views 28

A Missed Opportunity for Community Banks It's a classic tale: community banks sleepwalking while big players snatch up low-hanging fruit right in their own backyards. According to the latest report by Cornerstone Advisors, commissioned by Teslar Software, these banks are essentially leaving $106 billion on the table when it comes to consumer lending. That's not just chump...

Continue Reading
Navigating Holiday Sweets: Healthy Balancing Acts

Updated Category News Views 21

In the middle of the sweet madness that is the holiday season, Crispy Green and Dr. Nicole Avena are playing guide to families drowning in sugar. This isn't just a once-a-year Halloween headache; we're starting that sugar spiral early and letting it ride until the New Year approaches. It's an all-hands-on-deck situation if families want to dodge that sugar overload. Why...

Continue Reading
Charter Next Generation Unveils Gen 2 MDO-PE Films

Updated Category News Views 21

Peering Into CNG's Latest Innovation Charter Next Generation (CNG) just threw down a hefty gauntlet with its launch of next-gen machine-direction-oriented polyethylene (MDO-PE) solutions. They're pushing the envelope on what recycle-ready packaging can do, folks. Let's not mince words—other players in the field better have their game faces on. This ain't just another...

Continue Reading
IWP and VYRE Unveil 'The Plug' for VBNGtv Content

Updated Category News Views 21

Bringing Capital and Content Under One Roof There's something in the air as Itibari-Waynne & Partners (IWP) team up with the VYRE Network to crank out a fresh slate of content for VYRE Business News Global (VBNGtv). This partnership ain't just another splash in the buzzy world of digital media; it's like merging Wall Street with Hollywood. IWP, prepping to go full...

Continue Reading
Karoo Health Leaps Forward with New CCO Breton

Updated Category News Views 17

Change of Guard in Cardiac Health at Karoo Here's a move that might shake things up in the healthtech sector: Karoo Health just snagged Angela "Angie" Breton as their new Chief Commercial Officer. It's like putting a seasoned captain at the helm right before setting sail on uncharted waters. Breton's not just any captain—she's got a hefty 25 years of experience...

Continue Reading

Top 5 Most Recently Viewed Articles

Innofactor Plc's Recent Managerial Transactions Revealed

Updated Category News Views 47

Understanding Innofactor Plc's Recent Managerial Transactions Innofactor Plc recently completed important managerial transactions that signify its commitment to growth and transparency. The latest updates, outlined on a notable date, reveal key players and their roles within the organization. Key Figures in the Transactions The transactions include pivotal individuals...

Continue Reading
Aker ASA Increases Shareholding Through Recent Purchase

Updated Category News Views 164

Aker ASA Strengthens Employee Share Program Aker ASA has recently taken an important step in enhancing its shareholder value by purchasing 4,400 own shares at an average price of NOK 617.4108 per share. This acquisition took place on the Euronext Oslo Børs and is part of the company’s ongoing initiative to support its employees through a share program. Following this...

Continue Reading
Sanofi's Quarterly Performance: Dupixent Drives Growth

Updated Category News Views 225

Sanofi's Impressive Quarterly Sales Surge Past $14.5 Billion Sanofi SA (NASDAQ:SNY) has recently announced impressive third-quarter sales results totaling $14.55 billion (12.43 billion euros), surpassing the anticipated consensus of $14.46 billion. This performance marks a 2.3% increase compared to the previous year, with an even more robust growth of 7% when measured in...

Continue Reading
Revolutionizing Patient Access with Gifthealth and Occam Health

Updated Category News Views 414

Transforming Patient Access through Innovation Gifthealth has made a significant move by acquiring Occam Health Services, creating a groundbreaking digital pharmacy and patient access hub. This newly formed entity aims to redefine how biopharmaceutical companies engage with patients, ensuring quicker access to essential medications. As a leader in direct-to-patient...

Continue Reading
Winston & Strawn Welcomes Tax Expert Louis J. Jenull to Dallas

Updated Category News Views 53

Winston & Strawn Expands Tax Practice with New Partner Winston & Strawn LLP has made a notable addition to its legal team by bringing on Louis J. Jenull as a new partner in its Dallas office. His arrival is intended to strengthen the firm's Transactions Department, especially its Tax Practice, which is becoming increasingly vital in today's landscape of federal income...

Continue Reading